Madrigal Pharmaceuticals Inc [MDGL] stock prices are up 0.36% to $312.00 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The MDGL shares have gain 2.91% over the last week, with a monthly amount drifted -9.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $382. On April 22, 2024, BofA Securities initiated with a Underperform rating and assigned a price target of $150 on the stock. B. Riley Securities upgraded its rating to a Neutral and increased its price target to $270 on March 15, 2024. Citigroup initiated its recommendation with a Buy and recommended $382 as its price target on March 06, 2024. B. Riley Securities downgraded its rating to Sell for this stock on February 26, 2024, but kept the price target unchanged to $155. In a note dated December 20, 2022, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $170 to $250.
The stock price of Madrigal Pharmaceuticals Inc [MDGL] has been fluctuating between $168.25 and $368.29 over the past year. Currently, Wall Street analysts expect the stock to reach $315.75 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $312.00 at the most recent close of the market. An investor can expect a potential return of 1.2% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -7.06%, Pretax Profit Margin comes in at -6.69%, and Net Profit Margin reading is -6.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.72 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 308.51 points at the first support level, and at 305.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 314.73, and for the 2nd resistance point, it is at 317.45.
Ratios To Look Out For
It’s worth pointing out that Madrigal Pharmaceuticals Inc [NASDAQ:MDGL]’s Current Ratio is 5.98. On the other hand, the Quick Ratio is 5.93, and the Cash Ratio is 1.31. Considering the valuation of this stock, the price to sales ratio is 89.45, the price to book ratio is 8.84.
Transactions by insiders
Recent insider trading involved CRAVES FRED B, Director, that happened on Dec 03 ’24 when 3600.0 shares were sold. Director, CRAVES FRED B completed a deal on Nov 25 ’24 to sell 3400.0 shares. Meanwhile, Director CRAVES FRED B bought 10000.0 shares on Nov 25 ’24.
